Supplementary Materials for

Contribution of endogenous and exogenous antibodies to clearance of SARS-CoV-2 during

convalescent plasma therapy

Marconato et al.

Summary of supplementary tables and figures

Table S1: Study schedule

Table S2: Inclusion/Exclusion criteria of trial participants (plasma recipients)

- Table S3: Monitored parameters
- Table S4. Primary and secondary outcomes
- Table S5. Overview comorbidities
- Table S6: Safety outcomes
- Table S7: Severe adverse events (SAE)
- Table S8: Pulmonary ordinal outcome
- Table S9: Severity outcome of trial participants assessed by pulmonary ordinal outcome
- Table S10: Laboratory measures and clinical parameters

Table S11: Summary convalescent donor demographics

Table S12: Hazard ratios of time to viral clearance for binding and neutralizing parameters, presence

 of comorbidity and baseline viral load in nasopharyngeal swab.

- Fig. S1: Longitudinal assessment of primary and secondary outcomes
- Fig. S2: Phylogenetic analysis of the SARS-CoV-2 isolates from trial participants
- Fig. S3: No impact of neutralization activity on hospital release
- Fig. S4: Sensitivity analysis for impact of plasma on viral clearance
- Fig. S5: Spike specific binding and neutralizing antibodies are linked with rapid virus clearance
- Fig. S6: No impact on viral clearance when stratifying based on the Elecsys assay
- Fig. S7: Sensitivity of time to viral clearance when removing patients on remdesivir
- Fig. S8: High neutralizing plasma leads to faster virus decay in nasopharyngeal swabs
- Fig. S9: SARS-CoV-2 antibody reactivities are correlated within antibody classes
- Fig. S10: Evolution of SARS-CoV-2 antibodies in trial participants
- **Fig. S11:** Antibody response over time in the three trial participants incapable of mounting antibody response

Fig. S12: Sensitivity survival analysis adjusting for the impact of endogenous neutralization on virus clearance

Fig. S13: Sensitivity survival analysis adjusting for the impact of endogenous binding antibodies on virus clearance.

Table S1: Study schedule

Study period	Screening	Treat	ment pe	eriod	Safety follow-up			
Visit	1	2	3	4	5	6	7	8
Time (days)	0	0	1	2	4	9	23+/-1	72+/-1
Patient information and informed consent	x							
In-/exclusion criteria	x	х						
Medical history and demographic data	x							
Documentation of concomitant drugs	x	х	х	x	x	x	x	x
Body weight/height	x	х					x	x
Physical examination	x						x	x
Vital signs	x	х	х	x	x	x	х	x
Screening laboratory measurements	x							
Blood typing	x							
Safety laboratory tests	x	х	х	х	х	x	х	x
Laboratory measures	x	х	х	х	х	x	x	x
Urine pregnancy test	x							x
Samples for biobank (optional)	x				x	x	х	x
Administer study medication		х	х	х				
Severe adverse/adverse events	x	х	х	x	x	x	х	x

Table S2: Inclusion/exclusion criteria of trial participants

Inclusion <u>criteria:</u>	Exclusion <u>criteria:</u>
Inclusion criteria: A) Proven SARS-CoV-2 by PCR and hospitalization for COVID-19 in combination with either (1) or (2): (1) Age ≥ 50 AND (at least one): Pre-existing cardiovascular disease Diabetic disease Immunodeficiency/immunosuppression Neoplastic disease COPD or chronic liver disease or chronic renal failure (2) Age ≥ 18 AND (at least one): SpO2 ≤ 94% on room air or requiring supplemental oxygen at screening Typical changes on chest x-ray and/or lung-CT scan Immunosuppression or neoplastic disease	 Exclusion criteria: Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to class of drugs or the investigational product (FFP) Known IgA deficiency Cytokine Release Syndrome grade ≥ 3 Acute respiratory distress syndrome (ARDS) Patients already hospitalized in intensive care unit and/or already receiving mechanical ventilation Known or suspected non-compliance, drug or alcohol abuse Previous enrolment into the current study Enrolment of the investigator, his/her family members, employees and other dependent persons Women who are pregnant or breast feeding Intention to become pregnant during the course of the study
 Immunosuppression or neoplastic disease B) Written informed consent as documented by signature (Appendix Informed Consent Form) of the patient or, in case of inability, of the next relative/care-taking person. In the latter case, an independent doctor will also be involved and her/his signature will be required in order to enrol the patient. 	11. Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. Please note that female participants who are surgically sterilised/hysterectomised or post-menopausal for longer than 2 years are not considered as being of child bearing potential

Table S3: Monitored parameters

Monitored clinical parameter and laboratory measures	Baseline	Treatment period	Follow-up period		
	Day 0	Day 0-2, 9	23 +/-1, 72+/- 1		
Clinical parameters:					
Blood pressure (mmHg), Heart rate (bpm*) Respiratory rate (bpm**) Body temperature (°C, ear) Oxygen saturation (SpO2 (%))	x	x	х		
Laboratory measures:					
Blood count (WBC subsets), INR CRP (mg/L), Ferritin (ug/L), LDH (unit/L) D-dimer (mg/L), Fibrinogen (g/L), IL-6 Na, K, Ca, , Serum Creatinine (mg/dL) Liver enzymes: AST (SGOT) (U/L), ALT (SGPT) (U/L), γGT, Troponin I, Myoglobin Rapid urine test	x	x	х		
25-OH Vitamin, Albumin Urin sediment IgG, IgG subclasses, IgA, IgM PT, PTT	x				
SARS-CoV-2 antibody binding response (IgM, IgG, IgA response against S1, S2, RBD, N) SARS-CoV-2 neutralizing antibody binding titers (NT50)	x		х		
	х				
PCR for SARS-CoV-2 on nasal swab, plasma, BAL	х	х	х		

*beat per minute, **breaths per minute,

Table S4. Primary and secondary outcomes

Prir	mar	y outcomes:
(A)	Saf	fety measures
	1.	Assessment for
		 Transfusion related acute lung injury (TRALI)
		Anaphylactic reactions
		Hemolytic reactions
	2.	Clinical monitoring and measurement of laboratory parameters
		 During treatment episode: Day 0,1,2
		 Follow up : Day 4, Day 9, Day 23 +/- 1 and Day 72 +/- 1
(B)	Eff	icacy measures
	1.	Improvement of respiration:
		• Respiratory rate (breaths per minute, bpm), Oxygen saturation (SpO2
		(%))
	2.	Improvement of laboratory measures:
		• CRP (mg/L),
		• Ferritin (ug/L)
		• IL-6 (mg/L)
		• D-dimer (mg/L)
		• Fibrinogen (g/L)
		• LDH (unit/L)
	3.	Reduction of hospitalization duration
	4.	Prevention of ICU-admission or shortening of ICU-hospitalization
Sec	ond	lary outcomes:
	1.	Characterize humoral response (binding and neutralization) against SARS-
		CoV-2
	2.	Longitudinally assess viral shedding in nasopharyngeal swabs and blood
		samples

D	Gender	Comorbidity	Comorbidity type	Immune suppression	Impaired antibody response	Endogenous SARS-CoV- 2 neutralization at baseline	Log10 viral load NPS at baseline	Viral suppression blood at baseline	Remdesivir treatment	Steroid treatment	Convalescent plasma (NT50 low/high)	Clinical outcome at study completion (day 72)
1	Female	Yes	Solid organ transplant (kidney)	yes	No	Yes	4.7	Yes	No	No	high	1
2	Male	Yes	Cardiovascular disease	No	Yes	No	3.93	Yes	No	No	high	2
3	Female	Yes	Cardiovascular disease, Diabetic disease	No	No	Yes	4.48	Yes	No	No	high	1
4	Male	Yes	Cardiovascular disease, Neoplastic disease (Diffuse large-cell B cell NHL)	Yes	Yes	No	5.01	No	No	No	high	1
5	Male	Yes	Cardiovascular disease	No	No	Yes	4.34	Yes	No	No	low	1
6	Female	No		No	No	Yes	3.54	Yes	No	No	low	1
7	Male	Yes	Cardiovascular disease	No	No	Yes	4.65	Yes	No	No	low	1
8	Male	No		No	No	Yes	4.62	Yes	No	No	high	1
9	Female	No		No	No	Yes	5.32	No	No	No	high	1
10	Female	Yes	Cardiovascular disease, Diabetic disease	no	No	No	2.81	No	No	Yes	high	1
11	Male	Yes	Cardiovascular disease, Neoplastic disease (plasma cell leukaemia)	Yes	No	Yes	4.43	Yes	Yes	No	high	1
12	Male	Yes	Cardiovascular disease, Diabetic disease, COPD	No	No	No	5.86	No	No	No	low	1
13	Male	Yes	Cardiovascular disease	No	No	Yes	4.79	Yes	No	No	low	1
14	Male	No		No	No	Yes	3.77	No	No	No	high	1
15	Female	Yes	Cardiovascular disease, Neoplastic disease (CLL)	Yes	Yes	No	9.85	No	Yes	No	high	7
16	Male	Yes	Cardiovascular disease, Diabetic disease	No	No	Yes	3.91	No	No	No	low	1
17	Female	Yes	Cardiovascular disease, Diabetic disease	No	No	Yes	3.79	Yes	No	No	low	1
18	Female	No		No	No	No	5.8	No	Yes	No	low	2
19	Male	Yes	Cardiovascular disease, COPD	No	No	No	6.42	No	No	No	low	1
20	Male	No		No	No	No	3.85	No	No	No	low	1
21	Female	Yes	Cardiovascular disease, Diabetic disease	No	No	Na	4.39	Yes	No	No	high	1
22	Male	Yes	Cardiovascular disease, Chronic renal failure	No	No	Yes	5.15	Yes	No	No	high	1
23	Male	Yes	Cardiovascular disease, Diabetic disease	No	No	No	3.15	No	No	No	high	1
24	Male	Yes	Cardiovascular disease	No	No	Yes	6.97	No	No	Yes	high	2
25	Male	Yes	Cardiovascular disease	No	No	Yes	4.4	No	No	No	high	1
26	Male	Yes	Cardiovascular disease	No	No	No	5.56	No	No	Yes	low	2
27	Male	No		No	No	Yes	3.57	Yes	No	No	low	1
28	Female	Yes	Cardiovascular disease, Diabetic disease	No	No	Yes	5.19	No	No	Yes	high	1
29	Male	No		No	No	No	4.35	No	Yes	Yes	low	1
30	Male	Yes	Solid organ transplant (kidney)	Yes	No	No	4.56	Yes	No	No	high	1

Table S6: Safety outcomes

	Total
Complications of CPT therapy (safety), No (%)	
Transfusion Related Acute Lung Injury (TRALI)	0 (0%)
Anaphylactic Reactions (AR)	0 (0%)
Hemolytic Reactions (HR)	0 (0%)
Transfusion associated circulatory overload (TACO)	0 (0%)
Clinical and laboratory outcomes (efficacy), No (%)	
COVID-19 related death during the study	0 (0%)
Hospitalization in ICU	2/30 (6.67%)
Mechanical ventilation	2/30 (6.67%)

Table S7: Severe adverse events (SAE)

ID	Gender	Description of event	Description of intervention	Outcome	Comments, if relevant	
3	Female	NSTEMI	No specific treatment needed	improved	Possible correlation with COVID-19	
10	Female	Hospital acquired pneumonia (HAP)	antibiotics	resolved	COVID-19 resolved, HAP	
15	Female	Hospital acquired pneumonia (HAP)	antibiotics	death	COVID-19 resolved, HAP	
17	Female	Pulmonary Embolism	Anticoagulation with heparin and liquemin	resolved	Complication of COVID- 19	
18	Female	Respiratory insufficiency due to COVID-19	Patient transferred to the ICU and mechanical ventilation needed	resolved	-	
20	Male	Arthritis (right lateral malleolus)	Local corticosteroids	resolved	-	
26	Male	Respiratory insufficiency due to COVID-19	Patient transferred to the ICU and mechanical ventilation needed	resolved		

1= Can independently undertake usual activities with minimal or no symptoms
2= Symptomatic and currently unable to independently undertake usual activities but
no need of supplemental oxygen (or not above premorbid requirements)
3= Supplemental oxygen (<4 liters/min, or <4 liters/min above premorbid
requirements)
4= Supplemental oxygen (≥4 liters/min, or ≥4 liters/min above premorbid
requirements, but not high-flow oxygen)
5= Non-invasive ventilation or high-flow oxygen
6=Invasive ventilation, extracorporeal membrane oxygenation (ECMO), mechanical
circulatory support, or new receipt of renal replacement therapy
7=Death

	Be	efore/during the	erapy	Follow-u	ıp visits	Safety visits		
	Day 0	Day 1	Day 2	Day 4	Day 9	Day 23	Day 72 +/- 1	
						+/- 1		
Ordinal scale								
1	0 (0%)	0 (0%)	0 (0%)	1 (3%)	12 (40%)	21 (70%)	25 (83%)	
2	14							
	(47%)	16 (53%)	14 (47%)	16 (53%)	12 (40%)	6 (20%)	4 (13%)	
3	10							
	(33%)	9 (30%)	10 (33%)	9 (30%)	3 (10%)	1 (3%)	0 (0%)	
4	5 (17%)	4 (13%)	4 (13%)	2 (7%)	1 (3%)	0 (0%)	0 (0%)	
6	1 (3%)	1 (3%)	2 (7%)	2 (7%)	2 (7%)	1 (3%)	0 (0%)	
7	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (3%)	1 (3%)	

Table S9: Severity outcome of study participants assessed by pulmonary ordinal outcome

	Day 0	Day 1		Day2		Day 4	Day 4		Day 9		Day 23 +/- 1		Day 72 +/- 1	
Clinical parameters	median (IQR)	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	
Respiratory rate	18 (16-22)	18 (16.2-24)	0.56	18 (16.2-23.8)	0.4	18 (14-22)	0.12	14 (14-17.5)	0.0015	14 (14-14)	<0.001	14 (12-14)	<0.001	
Oxygen saturation level	94 (93-96)	94 (93-95)	0.56	94 (92.2-96)	0.45	95 (94-96)	0.36	97 (96-98)	<0.001	97 (96-98)	<0.001	97 (97-98)	<0.001	
Temperature (in °C)	37.1 (36.8-37.5)	37.1 (36.8-37.6)	0.85	37.1 (36.8-37.4)	0.85	36.9 (36.6-37.2)	0.043	36.8 (36.4-37)	0.028	36.8 (36.5-36.9)	<0.001	36.6 (36.5-36.8)	<0.001	
Laboratory parameters	median (IQR)	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	median (IQR)	p- value	
CRP	98.5 (66.2-143.8)	92.5 (53.8-117.2)	0.11	76.5 (42.2-99.2)	0.0038	40 (19.2-58)	<0.001	6.4 (3.5-18.8)	<0.001	1.4 (0.8-4.9)	<0.001	1.5 (0.6-2.6)	<0.001	
D-dimer	0.705 (0.5-1.2)	0.64 (0.4-1)	0.47	0.755 (0.5-1.1)	0.72	0.75 (0.5-1.1)	0.73	0.61 (0.4-1.4)	0.46	0.53 (0.4-0.8)	0.3	0.365 (0.3-0.5)	0.012	
Ferritin	691 (456.5-1219.8)	716 (425.8-1152)	0.86	768 (486-1389)	0.92	734.5 (327.2-1278.2)	0.75	454.5 (249.8-592)	0.04	234 (122-311.5)	<0.001	74 (43-170.2)	<0.001	
Fibrinogen	5.6 (5-6.1)	5.1 (4.7-5.5)	0.22	5.2 (4.7-6)	0.31	4.9 (4.3-5.8)	0.0062	4.1 (3.3-4.6)	<0.001	3.3 (2.9-3.8)	<0.001	3 (2.7-3.5)	<0.001	
IL-6	33.05 (18.6-53)	35.7 (21.2-67.3)	0.7	31 (14-49.7)	0.59	10.6 (4.8-26.6)	0.22	4.7 (3.3-10.3)	0.033	2.7 (1.9-4.1)	0.027	2.4 (1.9-4)	0.036	
LDH	547.5 (489.5-687.5)	592 (522.8-713.8)	0.64	587 (504-703)	0.83	550 (459-696)	0.74	477 (410.8- 545.8)	0.01	368 (326-458)	<0.001	401.5 (358.8-439.8)	<0.001	

Table S10: Longitudinal laboratory measures and clinical parameters of study participants

	Convalescent		Transfused (Transfused (n=30)				
	plasma (banked)	Transfused	NT50<250	NT50>250	p-value			
	(n=75)	(total)						
Age, median (IQR)	33 (21-45.5)	26.5 (20-38.5)	26 (19-36)	27 (20-39)	0.73			
Sex , No. (%)								
Male	75 (100%)	30 (100%)	13 (100%)	17 (100%)	1.00			
Blood type, No (%)								
А	34 (45%)	13 (43%)	6 (46%)	7 (41%)	1			
В	9 (12%)	5 (17%)	1 (8%)	4 (24%)	0.35			
AB	1 (1%)	1 (3%)	1 (8%)	0 (0%)	0.43			
0	28 (37%)	11 (37%)	5 (38%)	6 (35%)	1			
Symptoms								
duration, median								
(IQR)	12 (8-16.5)	10.5 (7-15.5)	10 (7-14)	11 (7-16)	0.74			

Table S11: Summary convalescent donor demographics

Table S12: Hazard ratios of time to viral clearance for binding and neutralizing parameters, presence of comorbidity and baseline viral load in nasopharyngeal swab. Estimates for both univariable and multivariable models are given.

Antibody	Antigen	Bindin	g/neutra	alizing antibod	ly		Baseline v	iral load			ty		
		Univariate model		Multivariate	model	Univariate	model	Multivari	ate model	Univari	ate model	Multivar	iate model
		HR (95% CI)	p-	HR (95% CI)	p-	HR (95% CI)	p-value	HR (95%	p-value	HR (95%	p-value	HR (95%	p-value
			value		value			CI)		CI)		CI)	
Neutralizatio								0.52		0.56		0.62	
n		2.4 [1,5.9]	0.05	3 [1.1,8.1]	0.026	0.53 [0.34,0.84]	0.0064	[0.32,0.84]	0.008	[0.22,1.4]	0.23	[0.22,1.8]	0.36
Roche								0.46		0.56		0.91	
		2.5 [1,6]	0.048	2.1 [0.75,5.6]	0.16	0.53 [0.34,0.84]	0.0064	[0.27,0.78]	0.0036	[0.22,1.4]	0.23	[0.33,2.5]	0.85
IgG	RBD							0.5		0.56		0.79	
		2.7 [1.1,6.5]	0.032	2.4 [0.93,6.2]	0.071	0.53 [0.34,0.84]	0.0064	[0.31,0.82]	0.0055	[0.22,1.4]	0.23	[0.28,2.2]	0.66
lgG	S1							0.5		0.56		0.8	
		1.5 [0.62,3.5]	0.38	3.5 [1.3,9.3]	0.013	0.53 [0.34,0.84]	0.0064	[0.3,0.82]	0.0061	[0.22,1.4]	0.23	[0.28,2.3]	0.68
lgG	S2							0.46		0.56		0.88	
		1.5 [0.63,3.6]	0.35	2.9 [1,7.9]	0.042	0.53 [0.34,0.84]	0.0064	[0.28,0.76]	0.0024	[0.22,1.4]	0.23	[0.32,2.5]	0.81
lgG	N							0.54		0.56		0.92	
		1.6 [0.66,3.8]	0.3	1.1 [0.44,2.6]	0.89	0.53 [0.34,0.84]	0.0064	[0.34,0.87]	0.012	[0.22,1.4]	0.23	[0.33,2.6]	0.88
lgG	RBD+S1+S2							0.49		0.56		0.85	
	+N	1.7 [0.72,4.1]	0.22	2.5 [0.96,6.4]	0.062	0.53 [0.34,0.84]	0.0064	[0.3,0.8]	0.0039	[0.22,1.4]	0.23	[0.31,2.3]	0.76
IgA	RBD							0.4		0.56		0.84	
		2.5 [1,6]	0.048	6.1 [1.9,20]	0.0027	0.53 [0.34,0.84]	0.0064	[0.23,0.7]	0.0011	[0.22,1.4]	0.23	[0.3,2.4]	0.74
IgA	S1							0.4		0.56		0.84	
		1.7 [0.71,4.1]	0.24	6.1 [1.9,20]	0.0027	0.53 [0.34,0.84]	0.0064	[0.23,0.7]	0.0011	[0.22,1.4]	0.23	[0.3,2.4]	0.74
IgA	S2							0.41		0.56		0.73	
		0.48 [0.19,1.2]	0.1	4 [1.4,12]	0.011	0.53 [0.34,0.84]	0.0064	[0.24,0.69]	0.00096	[0.22,1.4]	0.23	[0.26,2.1]	0.55
IgA	N			- [4 0 4 -]				0.4		0.56		0.83	0 =0
	555.64.63	2.2 [0.88,5.2]	0.092	5 [1.6,15]	0.0049	0.53 [0.34,0.84]	0.0064	[0.23,0.7]	0.0015	[0.22,1.4]	0.23	[0.3,2.3]	0.72
IgA	RBD+S1+S2	0.05 [0.4.0.0]	0.00	C 4 [4 0 20]	0 0007		0.0004	0.4	0.0014	0.56	0.00	0.84	0.74
	+N	0.95 [0.4,2.3]	0.92	6.1 [1.9,20]	0.0027	0.53 [0.34,0.84]	0.0064	[0.23,0.7]	0.0011	[0.22,1.4]	0.23	[0.3,2.4]	0.74
IgM	RBD		0.00		0.004		0.0004	0.5	0.0004	0.56	0.00	0.73	0.55
	64	1.7 [0.71,4.1]	0.23	2.5 [0.96,6.3]	0.061	0.53 [0.34,0.84]	0.0064	[0.31,0.83]	0.0064	[0.22,1.4]	0.23	[0.26,2]	0.55
Igivi	51		0.040		0.0000	0 50 [0 04 0 04]	0.0001	0.45	0.0001	0.56	0.00	0.75	0.50
1-14	63	2.5 [1,6]	0.048	4.1 [1.5,11]	0.0063	0.53 [0.34,0.84]	0.0064	[0.27,0.77]	0.0031	[0.22,1.4]	0.23	[0.27,2.1]	0.58
Igivi	52	1 7 [0 72 4 4]	0.22	27[172]	0.040	0 52 [0 24 0 84]	0.0001	0.46	0.0000	0.50	0.22	0.88	0.01
	N	1.7 [0.72,4.1]	0.22	2.7[1,7.2]	0.049	0.53 [0.34,0.84]	0.0064	[0.27,0.76]	0.0026	[0.22,1.4]	0.23	[0.32,2.5]	0.81
ISINI	IN		0 0 2 7	0.69 [0.26 1.0]	0.45	0 52 [0 24 0 84]	0.0064	0.57	0.029		0.22	0.98	0.08
		2.8 [1.1,0.7]	0.027	0.08 [0.26,1.8]	0.45	0.53 [0.34,0.84]	0.0064	[0.35,0.94]	0.028		0.23	[0.35,2.8]	0.98
ISINI	KBD+21+25	1 6 [0 60 4]	0.26	24[1205]	0.017	0 52 [0 24 0 84]	0.0064	0.43	0.0016	0.50	0.22		0.06
	+IN	1.0 [0.69,4]	0.26	3.4 [1.3,9.5]	0.017	0.53 [0.34,0.84]	0.0064	[0.25,0.72]	0.0010	[U.22,1.4]	0.23	[0.35,2.7]	0.90

Supplementary Figure legends

Fig. S1: Longitudinal assessment of primary and secondary outcomes. (A) Longitudinal clinical assessment of efficacy measures of all trial participants (n=30). Respiratory rate (breaths per minute (bpm)), level of oxygen saturation (SpO2%) and body temperature (°C). (B) Longitudinal laboratory measurements as defined in primary outcomes of all trial participants (n=30): C-reactive protein (CRP), D-dimer, Ferritin, Fibrinogen, IL-6 and LDH. Levels of significance are assessed by paired t-test comparing baseline to subsequent measures. Only significant p-values were shown. Numbers of trial participants with available measurements are indicated.

Fig. S2: Phylogenetic analysis of the SARS-CoV-2 isolates from 26 trial participants. Phylogenetic analysis of sequences derived from the 28 SARS-CoV-2 sequences, together with the background SARS-CoV-2 sequences extracted from gisaid that represent viral diversity across the WHO Switzerland region Zurich during the same time frame. Wuhan/WH04/2020 (EPI_ISL_406801), belonging to clade 19B, was chosen as the outgroup. The SARS-CoV-2 lineages are shown in the figure with the patient's sequences labeled with numbers. The scale bar indicates the number of nucleotide substitutions per site.

Fig. S3: No impact of neutralization activity on hospital release. Kaplan-Meier analysis assessing the time to hospital release according to the neutralization level of the plasma received. High neutralization activity NT50>250 (purple), low neutralization activity NT50< 250 (light green). The log-rank test is used to calculate the p-value.

Fig. S4: **Sensitivity analysis for impact of plasma on viral clearance**. (A) Kaplan Meier analysis and (B) survival function estimated with parametric survival model for interval-censored data assessing the time to viral clearance according to neutralization level excluding three trial participants incapable of mounting antibody response (n=27). (C) and (D) corresponding analyses to (A) and (B) but restricting the population to trial participants who did not receive remdesivir (n=26). (E) and (F) corresponding analyses to (A) and (B) but restricting the population to trial participants who did not receive remdesivir and were capable of mounting antibody response (n=24).

Fig. S5: Spike specific binding and neutralizing antibodies are linked with rapid virus clearance. Kaplan-Meier analyses of the effect of the different antibody reactivities stratified by response levels for all combinations of antibody

subtypes (IgG, IgA, IgA, IgM) and SARS-CoV-2 antigens (RBD, S1, S2 and NP) as well as the indicated sum of reactivities on the time to viral clearance. The effects of neutralization and binding activity as assessed with Roche S on the time to viral clearance are shown in the last row.

Fig. S6: No impact on viral clearance when stratifying based on the Elecsys assay. Forest plot depicting hazard ratios of univariable (grey) and multivariable (black) models of time to viral clearance including Elecsys Anti-SARS-CoV-2 (S) assay (U/ml). Multivariable analyses are corrected for baseline viral load and the presence of comorbidity. Low and high binding activity for each binding antibody parameter is stratified by the median binding reactivity.

Fig. S7: Sensitivity of time to viral clearance when removing patients on remdesivir. (A) Impact of antibody parameters on the time to viral clearance in multivariable parametric survival models when restricting to trial participants that did not receive remdesivir (n=26). Antibody reactivity of different antibody classes with SARS-CoV-2 antigens and neutralizing antibodies were included. Hazard ratios for individual antibody reactivities adjusted for the presence of comorbidity and the baseline viral load are shown. Significant results are marked in red. Low and high binding activity for each binding antibody parameter is stratified by the respective median binding reactivity. Low and high neutralization activity is stratified by a 50% neutralization titer of 250.

Fig. S8: High neutralizing plasma leads to faster virus decay in nasopharyngeal swabs. (A and B) Censored regression model estimating decay rate of viral load (log10 viral load) of nasopharyngeal swabs from time to treatment initiation when restricting to trial participants that did not receive remdesivir (n=26), according to (A) the level of neutralization (low neutralization NT50<250, light green; high neutralization, NT50>250, purple) or (B) level of binding defined by the ABCORA test sum of S1 SOC values. Low and high sum of S1 binding is stratified by the median binding reactivity. Significance was assessed using a two-sided t-test.

Fig. S9: **SARS-CoV-2 antibody reactivities are correlated within antibody classes.** Spearman correlation matrix assessing correlation between binding and neutralizing characteristics of the banked plasma samples. Levels of significance are assessed by asymptotic t approximation of Spearman's rank correlation. Color shading denotes correlation coefficient. Stars depict *p< 0.05, ** p< 0.01, *** p< 0.001.

Fig. S10: **Evolution of SARS-CoV-2 antibodies in trial participants**. Longitudinal binding antibody activity of trial participants (n=29) at baseline (day 0, purple), day 9 (green) and day 72 (yellow) assessed with the multiplex SARS-CoV-2 ABCORA test. Depicted are signal over cutoff (SOC) values of IgG, IgA, IgM against RBD and S1, S2 and N. Box plots depict the interquartile ranges with vertical lines representing the minimum and maximum values.

Fig. S11: Antibody response over time in the three trial participants incapable of mounting antibody response.

Longitudinal binding antibody activity for the three trial participants assessed with the multiplex SARS-CoV-2 ABCORA test. Depicted are signal over cutoff (SOC) values of IgG, IgA, IgM against RBD, S1, S2 and N.

Fig. S12: **Sensitivity survival analysis adjusting for the impact of endogenous neutralization on virus clearance.** (A) Forest plot showing the hazard ratios from univariable (grey) and multivariable (black) models of time to viral clearance for baseline viral load, the presence of comorbidity and both the exogenous and endogenous neutralization, when restricting the population to trial participants that did not receive remdesivir (n=26) (B) and restricting to trial participants that were capable of mounting antibody response (n=27).

Fig. S13: Sensitivity survival analysis adjusting for the impact of endogenous binding antibodies on virus clearance.

(A) Forest plot showing the hazard ratios from univariable (grey) and multivariable (black) models of time to viral clearance for baseline viral load, the presence of comorbidity and both the exogenous and endogenous S1 response (sum of IgG, IgA and IgM responses against S1), when restricting the population to trial participants that did not receive remdesivir (n=26) or (B) restricting to patients that were capable of mounting antibody response (n=26).



Α





Figure S4













		Trial participants excluding patients on remdesivir treatment (N=26)				
	Antibody type	Antigen		HR [95%CI]	p-value	
	Neutralization	Wuhan-1 HU-1		4.8 [1.6,14]	5.6x10 ⁻⁰³	
	Roche S	RBD		1.8 [0.63,5]	0.28	
	IgG	RBD S1 S2 N RBD+S1+S2+N		2.5 [0.89,6.8] 3.8 [1.3,11] 2.5 [0.87,7.1] 0.94 [0.37,2.4] 2.1 [0.79,5.6]	0.082 0.014 0.089 0.90 0.14	
Binding	IgA	RBD S1 S2 N RBD+S1+S2+N		5.4 [1.6,18] 5.4 [1.6,18] 4.6 [1.4,15] 4.4 [1.4,14] 5.4 [1.6,18]	6.7x10 ⁻⁰³ 6.7x10 ⁻⁰³ 0.012 0.012 6.7x10 ⁻⁰³	
	IgM	RBD S1 S2 N RBD+S1+S2+N		4.2 [1.4,12] 4.5 [1.5,14] 3 [1,8.6] 0.94 [0.34,2.6] 4.1 [1.4,12]	9.2x10 ⁻⁰³ 7.3x10 ⁻⁰³ 0.042 0.91 0.012	
	lgG+lgA+lgM	RBD S1 S2 N 0.1 0.2		3.8 [1.3,11] 3.9 [1.3,11] 2.1 [0.79,5.8] 0.94 [0.37,2.4]	0.014 0.012 0.13 0.90	
		Haza	ard Ratio for viral clearance			

Figure S8





Figure S10



Figure S11



A

Variables	Baseline	Subcategory		HR [95%CI]	p-value
Baseline viral load		+ 1 log10(VL)	⊢=−∣ ⊨−■−↓	0.5 [0.31,0.8] 0.42 [0.23,0.76]	4.1x10 ⁻⁰³ 3.9x10 ⁻⁰³
Comorbidity	No comorbidity	At least 1 comorbidity	┝──────┤	0.62 [0.21,1.8] 0.77 [0.21,2.8]	0.39 0.69
Neutralization (recipients)	NT50=100	NT50>100		0.66 [0.25,1.8] 0.42 [0.12,1.5]	0.41 0.18
Neutralization (donors)	NT50<250	NT50>250	 	2.9 [1.1,7.6] 5.2 [1.6,17]	0.036 6.7x10 ⁻⁰³
univariat	ele I multivariable	0.05	0.2 1 5 20 Hazard Ratio		
В					
Variables	Baseline	Subcategory		HR [95%CI]	p-value
Variables Baseline viral load	Baseline	Subcategory + 1 log10(VL)	⊢╼─┤ ┠─┲─┨	HR [95%CI] 0.51 [0.31,0.84] 0.5 [0.29,0.85]	p-value 7.6x10 ⁻⁰³ 0.011
Variables Baseline viral load Comorbidity	Baseline No comorbidity	Subcategory + 1 log10(VL) At least 1 comorbidity	┝╼═╌┥ ┝╼═╌┥ ┝───ड──┼┥ ┣───┺──┼┥	HR [95%CI] 0.51 [0.31,0.84] 0.5 [0.29,0.85] 0.44 [0.16,1.2] 0.46 [0.14,1.5]	p-value 7.6x10 ⁻⁰³ 0.011 0.11 0.19
Variables Baseline viral load Comorbidity Neutralization (recipients)	Baseline No comorbidity NT50=100	Subcategory + 1 log10(VL) At least 1 comorbidity NT50>100		HR [95%CI] 0.51 [0.31,0.84] 0.5 [0.29,0.85] 0.44 [0.16,1.2] 0.46 [0.14,1.5] 0.66 [0.25,1.8] 0.33 [0.093,1.2]	p-value 7.6x10 ⁻⁰³ 0.011 0.11 0.19 0.40 0.087
Variables Baseline viral load Comorbidity Neutralization (recipients) Neutralization (donors)	Baseline No comorbidity NT50=100 NT50<250	Subcategory + 1 log10(VL) At least 1 comorbidity NT50>100 NT50>250		HR [95%CI] 0.51 [0.31,0.84] 0.5 [0.29,0.85] 0.44 [0.16,1.2] 0.46 [0.14,1.5] 0.66 [0.25,1.8] 0.33 [0.093,1.2] 1.8 [0.69,4.6] 3.5 [1.1,11]	 p-value 7.6x10⁻⁰³ 0.011 0.11 0.19 0.40 0.087 0.23 0.034

A

